This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.
Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall
by Zacks Equity Research
Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.
TMO vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. EW: Which Stock Is the Better Value Option?
3 Reasons Why Edwards Lifesciences (EW) Is a Great Growth Stock
by Zacks Equity Research
Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.
McKesson (MCK) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) Pharmaceutical and Specialty Solutions unit is expected to have driven its fiscal Q2 results.
Edwards Lifesciences (EW) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 15.57% and 5.52%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Navigating The Healthcare Industry: Science Fiction Turns to Reality
by Panel Of Zacks Experts
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
Can Global Industrial Unit Drive Ecolab's (ECL) Q3 Earnings?
by Zacks Equity Research
Positive developments in the Global Industrial unit are expected to have driven Ecolab's (ECL) Q3 results.
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth, expected increase in bookings and solid show by Population Health, Revenue Cycle and IT Works are anticipated to get reflected in Cerner's (CERN) Q3 earnings.
What's in the Offing for Baxter's (BAX) Earnings in Q3?
by Zacks Equity Research
Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.
What's in Store for Varian Medical (VAR) in Q4 Earnings?
by Zacks Equity Research
Varian (VAR) is expected to have gained from core Proton Therapy platform in fiscal Q4.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Research Reports for Southern, Applied Materials & Vertex
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Southern Company (SO), Applied Materials (AMAT) and Vertex Pharmaceuticals (VRTX).
What's in Store for Intuitive Surgical (ISRG) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth are likely to aided Intuitive Surgical (ISRG) in Q3 earnings.
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) has been consistently delivering impressive results.
Will Edwards Lifesciences (EW) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
by Zacks Equity Research
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
What Makes Edwards Lifesciences (EW) a New Buy Stock
by Zacks Equity Research
Edwards Lifesciences (EW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) gains from recent impressive developments.